Diagnostic Value of SMARCE1 and CRISP3 Combined with Tumor Markers in Cervical Cancer

Abstract

Background: To investigate the diagnostic value of SMARCE1, cysteine-rich secreted protein 3 (CRISP3) combined with tumor markers in the diagnosis of cervical cancer. Methods: A total of 80 patients with cervical lesions who were diagnosed and treated in our hospital from January 2020 to March 2022 were selected and divided into control group (chronic cervicitis, n = 30) and observation group (cervical cancer, n = 50). Immunohistochemistry was used to detect the expression levels of SMARCE1 and CRISP3 in cervical tissue of the two groups of subjects, and the relationship between the expression of SMARCE1 and CRISP3 in cervical cancer tissue and the clinicopathological data of the patients was analyzed. In addition, the serum tumor marker levels of the two groups of subjects were detected, and the diagnostic value of SMARCE1 and CRISP3 combined with tumor markers in cervical cancer was analyzed. The female sexual function index (FSFI) and the functional assessment of cancer therapy-general (FACT-G) score were used to evaluate female sexual function and quality of life. Results: The positive expression rates of SMARCE1 and CRISP3 in the observation group were significantly higher than those in the control group (p < 0.05). There was no significant difference in the positive expression of SMARCE1 and CRISP3 among cervical cancer patients with age, lymph node metastasis and tumor node metastasis (TNM) classification stage (p > 0.05), and the lower the degree of tumor differentiation, the higher the positive expression rate of SMARCE1 and CRISP3 proteins (p < 0.05). The serum levels of carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125 and CA153 in the observation group were significantly higher than those in the control group (p < 0.05). The results of the receiver operating characteristic (ROC) curve analysis showed that the area under curve (AUC) values of SMARCE1, SMARCE1 + tumor markers, CRISP3, CRISP3 + tumor markers, SMARCE1, CRISP3 combined with tumor markers for the diagnosis of cervical cancer were 0.760, 0.851, 0.739, 0.810, and 0.944, respectively. Conclusions: SMARCE1 and CRISP3 are expressed in patients with cervical cancer, and CEA, CA125, and CA153 are expressed at high levels in the serum of patients with cervical cancer. The combined detection of SMARCE1 and CRISP3 combined with tumor markers has high clinical diagnostic value for cervical cancer.

Machine Learning-Enhanced Extraction of Biomarkers for High-Grade Serous Ovarian Cancer from Proteomics Data

“…Elevated CRISP3 in serum level is associated with poor treatment outcomes and also plays a role in predicting responses to treatments such as androgen deprivation therapy (ADT) and chemotherapy 51,52 . Downregulated CRISP3 has been shown in the breast 53 , cervical 54 , and ovarian cancer tissues 55,56 . In breast cancer, low levels of CRISP3 in tissue are correlated with poor survival rates 53 , whereas in ovarian cancer, increased expression of CRISP3 in serum is associated with HGSOC and poorer survival outcomes (Fig.…”